Abstract: Non-steroidal, anti-inflammatory drugs, followed by antibiotics, are the main causes of fixed drug eruption. They provoke one or several round erythematous or bullous lesions that recur in the same place after taking the causative medication. A positive patch test on residual, lesional skin can replace satisfactorily oral reintroduction. We describe the case of a 74-year-old woman with numerous, rounded, erythematous lesions on the trunk and recurrent blistering on the fifth right-hand finger, which developed a few hours after taking etoricoxib. Lesional patch testing with etoricoxib was positive and reproduced the typical pattern of a fixed drug eruption upon histopathology. We emphasize the specific reactivity of the etoricoxib patch test, and the capacity to reproduce the histologic pattern of the reaction.
INTRODUCTION
Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by one or multiple skin lesions that begin one to two weeks after the first exposure to the drug. These lesions present as erythematous and edematous round plaques, sometimes with a central blister. They can be found anywhere on the body but favor the oral mucosa, lips and genitalia. With subsequent exposures, lesions reactivate within 24 hours and then fade several days, often leaving a residual, post-inflammatory, grey-brown pigmentation.
After a further administration of the culprit drug, lesions appear at the same locations but may also emerge at new locations. In the presence of numerous lesions, it is termed generalized FDE and may be difficult to differentiate from erythema multiforme major, Stevens-Johnson Syndrome and toxic epidermal necrolysis, with which it shares histopathological findings. 1 The drugs most frequently associated with FDE are non-steroid, anti-inflammatory drugs (NSAIDs), followed by antibiotics. 
DISCUSSION
We present the case of a polymedicated, elderly patient with etoricoxib-induced FDE. Diagnosis was based on the typical clinical presentation and confirmed by a positive lesional patch test that reproduced the typical histopathology of FDE. Etoricoxib is a newly developed NSAID, a cyclo-oxygenase 2 selective inhibitor, rarely described as the culprit drug in FDE, which makes this a peculiar case. 7 In agreement with previous studies, patch testing on lesional skin was useful to confirm etoricoxib as the culprit drug in this FDE case. 7,2 It should be highlighted that patch testing must be performed on residual lesional areas, where epidermal CD8+ memory T lymphocytes are retained for many years 6 . This explains the exclusive reactivity of these locations facing oral rechallenge and probably facilitates reactivation after cutaneous exposure due to patch testing.
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Fixed drug eruption by etoricoxib confirmed by patch test 653
Positive patch test at 24 hours with erythema and infiltration of the patch test area on residual lesions, and negative patch test when performed on non-involved skin (red arrow)
Figure 2:
Highlight of reactivation of the skin lesion in the fifth right-hand finger after contact test (Figure 4) . 2, 7, 9 With an aging population, the growing consumption of medication and the commercialization of new drugs by the pharmaceutical industry, there is an increased incidence in adverse cutaneous drug reactions. 
